-
Loading metrics
I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment
-
Stelios Pavlidis,
Roles Conceptualization, Formal analysis, Investigation, Methodology, Writing – review & editing
Affiliations Janssen Research & Development Ltd, High Wycombe, United Kingdom, National Heart and Lung Institute, Imperial College & Biomedical Research Unit, Royal Brompton & Harefield NHS Trust, London, United Kingdom, Data Science Institute, Imperial College London, London, United Kingdom
⨯ -
Calixte Monast,
Roles Formal analysis, Methodology, Writing – review & editing
Affiliation Janssen Research & Development LLC, United States of America
⨯ -
Matthew J. Loza,
Roles Conceptualization, Investigation, Methodology, Writing – review & editing
Affiliation Janssen Research & Development LLC, United States of America
⨯ -
Patrick Branigan,
Roles Conceptualization, Writing – review & editing
Affiliation Janssen Research & Development LLC, United States of America
⨯ - Kiang F. Chung,
- Ian M. Adcock,
-
Yike Guo,
Roles Supervision, Writing – review & editing
Affiliation Data Science Institute, Imperial College London, London, United Kingdom
⨯ - Anthony Rowe,
-
Frédéric Baribaud
Roles Conceptualization, Methodology, Supervision, Writing – review & editing
* E-mail: FBaribau@its.jnj.com
Affiliation Janssen Research & Development LLC, United States of America
⨯
http://orcid.org/0000-0001-9435-6064
I_MDS: an inflammatory bowel disease molecular activity score to classify patients with differing disease-driving pathways and therapeutic response to anti-TNF treatment
- Stelios Pavlidis,
- Calixte Monast,
- Matthew J. Loza,
- Patrick Branigan,
- Kiang F. Chung,
- Ian M. Adcock,
- Yike Guo,
- Anthony Rowe,
- Frédéric Baribaud
-
- Published: April 30, 2019
- https://doi.org/10.1371/journal.pcbi.1006951